AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) … Get the latest from our blog.AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.AIM ImmunoTech’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases.AIM ImmunoTech is committed to providing up to date information to shareholders, analysts, and potential investors. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. Hover over the logos to learn more about the companies who made this project possible. Get the latest from our blog.AIM ImmunoTech’s flagship products include Ampligen® (Rintatolimod), a developmental first-in-class drug of large macromolecular RNA molecules.AIM ImmunoTech platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Under the Patent Cooperation Treaty of 1970, which provides international protections for patents, the three provisional patent applications can convert to international patent applications based on the date of their filings. All Rights Reserved. Alternatively, direct national filings in many countries are possible under the Paris Convention for the Protection of Industrial Property of 1883 - an international agreement. Ampligen achieved a 100% survival rate - as compared to 100% mortality - at clinically achievable human dosage levels in animal experiments. In the this portion, patients will receive the combination regimen or best available care. No assurance can be made as to any future clinical trials related to the matter herein.
The trial’s Phase I part is expected to involve 12 to 24 patients who will be given Ampligen and interferon alfa-2b at escalating doses. AIM ImmunoTech wins approval to import chronic fatigue syndrome drug Ampligen to Argentina The drug may have a role in treating coronavirus patients who develop chronic fatigue syndrome AIM ImmunoTech is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This is our effort to make a difference in this worldwide threat posed by the Wuhan coronavirus. Protocols for those trials are in final stages of development. It is for this reason that I directed the AIM ImmunoTech team to reexamine the antiviral properties of Ampligen in conjunction with the known genomic … The company's three provisional patent applications include: 1) Ampligen as a therapy for the Wuhan coronavirus; 2) Ampligen as part of a proposed intranasal universal coronavirus vaccine that combines Ampligen with inactivated Wuhan coronavirus, conveying immunity and cross-protection and; 3) a high-volume manufacturing process for Ampligen. AIM ImmunoTech has signed a clinical trial agreement (CTA) with Roswell Park Comprehensive Cancer Center for a Phase I/IIa clinical trial of Ampligen (rintatolimod) in combination with interferon alfa-2b for the treatment of Covid-19 patients with cancer. Viedoc Technologies offers a new way of looking at data... We use them to give you the best experience. It is for this reason that I directed the AIM ImmunoTech team to reexamine the antiviral properties of Ampligen in conjunction with the known genomic … About AIM ImmunoTech Inc. AIM has recently produced more than 10,000 vials of Ampligen.